GENFIT S.A. Releases Half-Year Financial Report for 2025

An update from Genfit SA ( (GNFT) ) is now available.

On September 22, 2025, GENFIT S.A. released its Half-Year Business and Financial Report for the period ending June 30, 2025. The report details the company’s ongoing R&D programs, including developments in their ACLF franchise and other serious diseases. The report also highlights the company’s strategic outlook and financial performance, providing insights into GENFIT’s industry positioning and potential implications for stakeholders.

The most recent analyst rating on (GNFT) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Genfit SA stock, see the GNFT Stock Forecast page.

Spark’s Take on GNFT Stock

According to Spark, TipRanks’ AI Analyst, GNFT is a Neutral.

Genfit SA’s overall stock score reflects a strong financial recovery with significant revenue growth and improved cash flow. The technical indicators are positive, supporting a favorable short-term outlook. However, the high P/E ratio suggests potential overvaluation, which is a significant risk factor. The absence of earnings call insights and corporate events limits additional context.

To see Spark’s full report on GNFT stock, click here.

More about Genfit SA

GENFIT is a biopharmaceutical group focused on developing treatments for liver diseases, particularly rare and life-threatening conditions. Founded in 1999, the company has a strong history in liver disease research and development, with a diverse R&D portfolio targeting Acute-on-Chronic Liver Failure (ACLF) and other serious diseases. GENFIT’s expertise is highlighted by the approval of Iqirvo® (elafibranor) for Primary Biliary Cholangitis by major regulatory agencies.

Average Trading Volume: 3,452

Technical Sentiment Signal: Buy

Current Market Cap: $211.6M

See more insights into GNFT stock on TipRanks’ Stock Analysis page.